Shugushev Kh Kh, Malakhov V I, Shestakova N V
Ter Arkh. 1986;58(3):49-52.
Fifty-six patients with frequently occurring paroxysms of atrial fibrillation were examined for the clinical efficacy of a new antiarrhythmic drug etacyzine (a diethylamine analog of etmozin). The use of the drug in doses of 50 to 70 mg intravenously and in doses in 150 to 200 mg per os a day removed and prevented the occurrence of atrial fibrillation paroxysms in 60 to 65% of cases, whereas etmozin in doses of 50 mg intravenously and 600 to 800 mg per os day did not produce any positive anti-arrthythma effect in the patients. The prolonged use of etacyzine (up to 1 year and over) exerted a beneficial antiarrhythmic action almost in all the patients. The drug did not provoke any serious side effects. However, in some patients, the use of the drug promoted a substantial prolongation of the P-Q interval and widening of the QRS complex of the ECG. In one female patient, the drug caused a paradoxical repetition of the ventricular rhythm.
对56例频发阵发性心房颤动患者进行了一种新型抗心律失常药物依他西嗪（乙吗噻嗪的二乙胺类似物）的临床疗效检查。静脉注射50至70毫克剂量以及每日口服150至200毫克剂量的该药物，在60%至65%的病例中消除并预防了心房颤动阵发性发作的发生，而静脉注射50毫克且每日口服600至800毫克剂量的乙吗噻嗪对这些患者未产生任何积极的抗心律失常作用。长期使用依他西嗪（长达1年及以上）几乎对所有患者都发挥了有益的抗心律失常作用。该药物未引发任何严重的副作用。然而，在一些患者中，使用该药物促使心电图的P-Q间期显著延长以及QRS波群增宽。在一名女性患者中，该药物导致了室性心律的反常重复。
